Revelation Pharma (Osceola Capital) Acquires Harrow Health's Non‑Ophthalmic Compounding Business
October 12, 2022
Osceola Capital-backed Revelation Pharma has acquired the non-ophthalmic compounding business of NASDAQ-listed Harrow Health as the twelfth add-on to the Revelation platform. The deal lets Revelation expand its national footprint of 503A and 503B compounding pharmacies while Harrow focuses solely on ophthalmic medications.
- Targets
- Harrow Health (non-ophthalmic compounding business)
- Sellers
- Harrow Health
- Platforms
- Revelation Pharma Corporation
- Industry
- Healthcare Services
- Location
- Tennessee, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.